Information Regarding Active Biotech AB's Candidate Drug Laquinimod
Published: Nov 02, 2011
LUND, SWEDEN--(Marketwire - November 02, 2011) -
During Teva's 3(rd) Quarter 2011 Results Conference Call today, Teva's CEO Shlomo Yanai commented "Last week we held a meeting with the FDA to discuss the NDA for laquinimod. Following the meeting we now believe that it would be premature to file NDA at this time. The FDA has offered to work with us to determine the best design for conducting an additional trial".
Active Biotech AB (publ)
President & CEO
ABOUT ACTIVE BIOTECH
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex™ for RA. Please visit www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund Tel: +46 46 19 20 00 Fax: +46 46 19 11 00
Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 14:30 a.m. CET on November 2, 2011.
Information regarding Active Biotech?s candidate drug laquinimod: http://hugin.info/1002/R/1560205/482628.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
For further information, please contact
President & CEO
Tel: +46 46 19 20 95